Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Pascale Desrumaux, Christine Jeoffrion, Naouelle Bouterfas, Sabine De Bosscher & Méthode C. Boudenghan. (2018) Workplace bullying: How do bystanders’ emotions and the type of bullying influence their willingness to help?. Nordic Psychology 70:4, pages 259-277.
Read now
Read now
John A Arnott & Sonia Lobo Planey. (2012) The influence of lipophilicity in drug discovery and design. Expert Opinion on Drug Discovery 7:10, pages 863-875.
Read now
Read now
T. Peyret & K. Krishnan. (2011) QSARs for PBPK modelling of environmental contaminants. SAR and QSAR in Environmental Research 22:1-2, pages 129-169.
Read now
Read now
David FV Lewis, Yuko Ito & Brian G Lake. (2010) Quantitative structure-activity relationships (QSARs) for inhibitors and substrates of CYP2B enzymes: importance of compound lipophilicity in explanation of potency differences. Journal of Enzyme Inhibition and Medicinal Chemistry 25:5, pages 679-684.
Read now
Read now
Michael J Waring. (2010) Lipophilicity in drug discovery. Expert Opinion on Drug Discovery 5:3, pages 235-248.
Read now
Read now
D. F. V. Lewis & Y. Ito. (2009) Human P450s involved in drug metabolism and the use of structural modelling for understanding substrate selectivity and binding affinity. Xenobiotica 39:8, pages 625-635.
Read now
Read now
Paul Czodrowski, Jan M Kriegl, Stefan Scheuerer & Thomas Fox. (2009) Computational approaches to predict drug metabolism. Expert Opinion on Drug Metabolism & Toxicology 5:1, pages 15-27.
Read now
Read now
David F.V. Lewis, Brian G. Lake, Yuko Ito & Maurice Dickins. (2006) Lipophilicity Relationships in Inhibitors of CYP2C9 and CYP2C19 Enzymes. Journal of Enzyme Inhibition and Medicinal Chemistry 21:4, pages 385-389.
Read now
Read now
David F.V. Lewis, Brian G. Lake & Maurice Dickins. (2006) Quantitative structure–activity relationships (QSARs) in CYP3A4 inhibitors: The importance of lipophilic character and hydrogen bonding. Journal of Enzyme Inhibition and Medicinal Chemistry 21:2, pages 127-132.
Read now
Read now
Articles from other publishers (28)
Jaebeom Park, Minji Kang, Ahyoung Lim, Kyung-Jin Cho, Chong Hak Chae, Byumseok Koh & Hongjun Jeon. (2023) Synthesis and evaluation of tirbanibulin derivatives: a detailed exploration of the structure–activity relationship for anticancer activity. RSC Advances 13:50, pages 35583-35591.
Crossref
Crossref
Xuan Yang, Han Wee Ong, Rebekah J. Dickmander, Jeffery L. Smith, Jason W. Brown, William Tao, Edcon Chang, Nathaniel J. Moorman, Alison D. Axtman & Timothy M. Willson. (2023)
Optimization of 3-Cyano-7-cyclopropylamino-pyrazolo[1,5-
a
]pyrimidines toward the Development of an In Vivo Chemical Probe for CSNK2A
. ACS Omega 8:42, pages 39546-39561.
Crossref
Crossref
Mieneke Pouwelse, Roelie Mulder & Eva Gemzøe Mikkelsen. 2021. Pathways of Job-related Negative Behaviour. Pathways of Job-related Negative Behaviour
385
422
.
. 2020. ANSI/AAMI/ISO 10993-16:2017; Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables. ANSI/AAMI/ISO 10993-16:2017; Biological evaluation of medical devices—Part 16: Toxicokinetic study design for degradation products and leachables.
Zhennan Zhang, Zhe Sun, Yaozhen Ye & Xianqin Wang. (2020) Determination of Main Compositions in Phyllanthus Urinaria and its Effects on Cyp450 in Rats. Current Pharmaceutical Analysis 16:5, pages 520-528.
Crossref
Crossref
Yusra Sajid Kiani & Ishrat Jabeen. (2019) Lipophilic Metabolic Efficiency (LipMetE) and Drug Efficiency Indices to Explore the Metabolic Properties of the Substrates of Selected Cytochrome P450 Isoforms. ACS Omega 5:1, pages 179-188.
Crossref
Crossref
Yusra Sajid Kiani & Ishrat Jabeen. (2019) Exploring the Chemical Space of Cytochrome P450 Inhibitors Using Integrated Physicochemical Parameters, Drug Efficiency Metrics and Decision Tree Models. Computation 7:2, pages 26.
Crossref
Crossref
Zhoupeng Zhang & Wei Tang. (2018) Drug metabolism in drug discovery and development. Acta Pharmaceutica Sinica B 8:5, pages 721-732.
Crossref
Crossref
Nagarajan Muthukaman, Sanjay Deshmukh, Macchindra Tambe, Dnyandeo Pisal, Shital Tondlekar, Mahamadhanif Shaikh, Neelam Sarode, Vidya G. Kattige, Pooja Sawant, Monali Pisat, Vikas Karande, Srinivasa Honnegowda, Abhay Kulkarni, Dayanidhi Behera, Satyawan B. Jadhav, Ramchandra R. Sangana, Girish S. Gudi, Neelima Khairatkar-Joshi & Laxmikant A. Gharat. (2018) Alleviating CYP and hERG liabilities by structure optimization of dihydrofuran-fused tricyclic benzo[ d ]imidazole series – Potent, selective and orally efficacious microsomal prostaglandin E synthase-1 (mPGES-1) inhibitors: Part-2. Bioorganic & Medicinal Chemistry Letters 28:7, pages 1211-1218.
Crossref
Crossref
Mieneke Pouwelse, Roelie Mulder & Eva Gemzøe Mikkelsen. 2018. Pathways of Job-related Negative Behaviour. Pathways of Job-related Negative Behaviour
1
39
.
Lydia Benkaidali, François André, Gautier Moroy, Bahoueddine Tangour, François Maurel & Michel Petitjean. (2017) The Cytochrome P450 3A4 has three Major Conformations: New Clues to Drug Recognition by this Promiscuous Enzyme. Molecular Informatics 36:10, pages 1700044.
Crossref
Crossref
Anita Emmerstorfer, Miriam Wimmer-Teubenbacher, Tamara Wriessnegger, Erich Leitner, Monika Müller, Iwona Kaluzna, Martin Schürmann, Daniel Mink, Günther Zellnig, Helmut Schwab & Harald Pichler. (2015)
Over-expression of
ICE2
stabilizes cytochrome P450 reductase in
Saccharomyces cerevisiae
and
Pichia pastoris
. Biotechnology Journal 10:4, pages 623-635.
Crossref
Crossref
John Eksterowicz, Dan A. Rock, Brooke M. Rock, Larry C. Wienkers & Robert S. Foti. (2014) Characterization of the Active Site Properties of CYP4F12. Drug Metabolism and Disposition 42:10, pages 1698-1707.
Crossref
Crossref
Oraphan Phuangsawai, Supa Hannongbua & Mathew Paul Gleeson. 2014. Drug Metabolism Prediction. Drug Metabolism Prediction
319
350
.
Alessandra PirovanoMark A. J. HuijbregtsAd M. J. RagasA. Jan Hendriks. (2012)
Compound Lipophilicity as a Descriptor to Predict Binding Affinity (1/
K
m
) in Mammals
. Environmental Science & Technology 46:9, pages 5168-5174.
Crossref
Crossref
Thomas Peyret & Kannan Krishnan. (2012) Quantitative Property-Property Relationship for Screening-Level Prediction of Intrinsic Clearance of Volatile Organic Chemicals in Rats and Its Integration within PBPK Models to Predict Inhalation Pharmacokinetics in Humans. Journal of Toxicology 2012, pages 1-22.
Crossref
Crossref
Igor Shamovsky, Chris de Graaf, Lisa Alderin, Malena Bengtsson, Håkan Bladh, Lena Börjesson, Stephen ConnollyHazel J. DykeMarco van den HeuvelHenrik Johansson, Bo-Göran Josefsson, Anna Kristoffersson, Tero Linnanen, Annea Lisius, Roope MännikköBo Nordén, Steve PriceLena Ripa, Didier Rognan, Alexander Rosendahl, Marco Skrinjar & Klaus Urbahns. (2009) Increasing Selectivity of CC Chemokine Receptor 8 Antagonists by Engineering Nondesolvation Related Interactions with the Intended and Off-Target Binding Sites. Journal of Medicinal Chemistry 52:23, pages 7706-7723.
Crossref
Crossref
Regina Appiah-Opong, Iwan de Esch, Jan N.M. Commandeur, Mayagustina Andarini & Nico P.E. Vermeulen. (2008) Structure–activity relationships for the inhibition of recombinant human cytochromes P450 by curcumin analogues. European Journal of Medicinal Chemistry 43:8, pages 1621-1631.
Crossref
Crossref
Igor Shamovsky, Stephen Connolly, Laurent David, Svetlana Ivanova, Bo Nordén, Brian Springthorpe & Klaus Urbahns. (2008) Overcoming Undesirable hERG Potency of Chemokine Receptor Antagonists Using Baseline Lipophilicity Relationships. Journal of Medicinal Chemistry 51:5, pages 1162-1178.
Crossref
Crossref
Thomas Fox & Jan M. Kriegl. 2007.
63
81
.
Kazuki Shimizu, Akira Kawase, Tsuyoshi Haneishi, Yasuharu Kato, Kazutomo Kinoshita, Masayuki Ohmori, Yoshiyuki Furuta, Takashi Emura, Nobuaki Kato, Tetsuya Mitsui, Koji Yamaguchi, Keiichi Morita, Nobuo Sekiguchi, Tessai Yamamoto, Tomochika Matsushita, Shin Shimaoka, Atsuko Sugita & Kazumi Morikawa. (2006) Design and evaluation of new antipsoriatic antedrug candidates having 16-en-22-oxa-vitamin D3 structures. Bioorganic & Medicinal Chemistry Letters 16:12, pages 3323-3329.
Crossref
Crossref
David F.V. Lewis, Brian G. Lake, Yuko Ito & Pavel Anzenbacher. (2006) QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIPS (QSARs) WITHIN CYTOCHROMES P450 2B (CYP2B) SUBFAMILY ENZYMES: THE IMPORTANCE OF LIPOPHILICITY FOR BINDING AND METABOLISM. Drug Metabolism and Drug Interactions 21:3-4.
Crossref
Crossref
David F.V. Lewis, Yuko Ito & Peter S. Goldfarb. (2005) Cytochrome P450 structures and their substrate interactions. Drug Development Research 66:1, pages 19-24.
Crossref
Crossref
Xiang He, Max J. Cryle, James J. De Voss & Paul R. Ortiz de Montellano. (2005) Calibration of the Channel That Determines the ω-Hydroxylation Regiospecificity of Cytochrome P4504A1. Journal of Biological Chemistry 280:24, pages 22697-22705.
Crossref
Crossref
Matthew J. Walker. (2004) Training ACD/LogP with Experimental Data. QSAR & Combinatorial Science 23:7, pages 515-520.
Crossref
Crossref
David F.V. Lewis, Miriam N. Jacobs & Maurice Dickins. (2004) Compound lipophilicity for substrate binding to human P450s in drug metabolism. Drug Discovery Today 9:12, pages 530-537.
Crossref
Crossref
David F. V. Lewis. (2003) Quantitative structure–activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and induction of P450s. InflammoPharmacology 11:1, pages 43-73.
Crossref
Crossref
D.F.V. Lewis, B.G. Lake, M. Dickins & P.S. Goldfarb. (2002) Molecular Modelling of CYP2B6 Based on Homology with the CYP2C5 Crystal Structure: Analysis of Enzyme-Substrate Interactions. Drug Metabolism and Drug Interactions 19:2.
Crossref
Crossref